CNS Tumor Clinical Trial
— VIGILANTOfficial title:
Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice
Verified date | November 2023 |
Source | Arbor Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.
Status | Active, not recruiting |
Enrollment | 272 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent, by the patient or a legally acceptable representative, obtained before any registry-related activities are undertaken. The informed consent must be signed within 14 calendar days after surgery. 2. Male and female patients, greater than or equal to 18 years of age or age of majority in state of residence. 3. Patients planning to receive Gliadel Wafer, or having already received Gliadel Wafer and having signed consent to enroll in the registry within 14 calendar days after surgery for treatment of central nervous system (CNS) tumor(s), or are currently enrolled in another study where they received Gliadel Wafer. 4. Signed release form, by the patient or a legally acceptable representative, permitting abstraction of the patient's medical records at Baseline and during participation in the registry. Exclusion Criteria: 1. The patient is enrolled in an interventional clinical trial, in which treatment for CNS tumor(s) is managed through a protocol that excludes Gliadel Wafer treatment. 2. Any abnormality or medical condition that, at the discretion of the Investigator, may put the patient at increased risk by participating in this registry. 3. Any other reason that, in the Investigator's opinion, makes the patient unsuitable to participate in this registry. |
Country | Name | City | State |
---|---|---|---|
United States | Albany Medical Center Hospital | Albany | New York |
United States | Emory University Hospital | Atlanta | Georgia |
United States | University of Colorado School of Medicine | Aurora | Colorado |
United States | Johns Hopkins University School of Medicine | Baltimore | Maryland |
United States | McLaren Bay Neurology Associates | Bay City | Michigan |
United States | Depaul Hospital | Bridgeton | Missouri |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Mount Carmel Neurosurgery | Columbus | Ohio |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Jfk Medical Center | Edison | New Jersey |
United States | Beacon Medical Group | Elkhart | Indiana |
United States | Vidant Medical Center | Greenville | North Carolina |
United States | Spine and Neuro Center | Huntsville | Alabama |
United States | Brain Tumor Center | Lake Success | New York |
United States | Western Regional Ctr for Brain and Spine Surgery | Las Vegas | Nevada |
United States | Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire |
United States | David Geffen School of Medicine at UCLA; Departments of Neurosurgery and Pathology at the | Los Angeles | California |
United States | Grand Strand Medical Center | Myrtle Beach | South Carolina |
United States | Oschner Medical Center | New Orleans | Louisiana |
United States | University of Oklahoma - Stevenson Cancer Center | Oklahoma City | Oklahoma |
United States | Baptist Health Paducah | Paducah | Kentucky |
United States | University of Pennsylvania Health System | Philadelphia | Pennsylvania |
United States | Borrow Neurological Institute | Phoenix | Arizona |
United States | St. Louis University Hospital | Saint Louis | Missouri |
United States | University of California, San Francisco Department of Neurological Surgery | San Francisco | California |
United States | Spine Group Arizona At Honorhealth Scottsdale Osborn Medical Center | Scottsdale | Arizona |
United States | University of Washington School of Medicine | Seattle | Washington |
United States | Crouse Neuroscience Institute | Syracuse | New York |
United States | Baycare Medical Group | Tampa | Florida |
United States | Neurological Associates of Tucson, DBA Center for Neurosciences | Tucson | Arizona |
United States | Wake Forest Baptist Med Center | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Arbor Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To evaluate health care utilization though length of hospital stays for the primary procedure and any subsequent hospitalizations in patients treated with Gliadel Wafer | number of days in hospital following Gliadel insertion | up to 3 years | |
Other | To explore patient survival status based upon biomarker status. | up to 3 years | ||
Primary | To evaluate the overall survival rate for patients treated with Gliadel Wafer | Time from Gliadel placement to death | up to 3 years | |
Primary | To evaluate the disease-specific survival rate for patients treated with Gliadel Wafer | Time from Gliadel placement to death due to CNS tumor | up to 3 years | |
Primary | To evaluate the progression-free survival rate for patients treated with Gliadel Wafer | Time from Gliadel placement to diagnosis of recurrent CNS tumor | up to 3 years | |
Secondary | To evaluate the serious adverse events (SAEs) in patients treated with Gliadel Wafer. | Frequency of SAEs | up to 3 years | |
Secondary | To evaluate events of interest (EOI) in patients treated with Gliadel Wafer. | Frequency of EOIs | up to 3 years | |
Secondary | To evaluate nonserious, suspected adverse drug reactions (ADRs) in patients treated with Gliadel Wafer. | frequency of ADRs | up to 3 years | |
Secondary | To evaluate change in patient health status over time via patient reported outcomes (PRO) | Change in FACT-Br score from baseline to end of study participation | up to 3 years | |
Secondary | To evaluate change in patient health status over time via a practitioner/proxy reported scale | Change in KPS score from baseline to end of study participation | up to 3 years | |
Secondary | To evaluate the the reasons a physician does not insert Gliadel Wafers, in patients who were considered and consented for this Registry prior to the tumor resection procedure | reasons for screen failure | up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06036394 -
Artificial Intelligence in CNS Radiation Oncology
|
||
Withdrawn |
NCT05222165 -
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
|
Phase 1/Phase 2 | |
Recruiting |
NCT03838042 -
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05300113 -
Artificial Intelligence Neuropathologist
|
||
Completed |
NCT04334239 -
Effectiveness of Care in Certified Cancer Centres in Germany
|
||
Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
Withdrawn |
NCT05952687 -
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
|
Phase 1 | |
Terminated |
NCT02988726 -
Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
|
Phase 2 | |
Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
Not yet recruiting |
NCT06441331 -
Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
|
Phase 1 | |
Recruiting |
NCT04706676 -
Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer
|
N/A | |
Recruiting |
NCT04773782 -
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04023669 -
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
|
Phase 1 | |
Recruiting |
NCT05982691 -
Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors
|
||
Recruiting |
NCT04732065 -
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
|
Phase 1 | |
Recruiting |
NCT05480904 -
Characterizing Sleep Among Long-term Survivors of Childhood Cancer
|